On the afternoon of February 19, at the press conference held by the joint prevention and control mechanism of the State Council, Wu Liangyou, deputy director of the disease control bureau of the National Health Commission, said that recently, with the approval of the joint prevention and control mechanism of the State Council, the National Health Commission has begun to deploy covid-19 vaccine to strengthen immunization in sequence.
Wu Liangyou said that after the implementation of the sequential immunization strategy, the target population who have completed the whole process of inactivated vaccine vaccination of Sinopharm Zhongsheng Beijing company, Beijing Kexing company and Sinopharm Zhongsheng Wuhan company can choose the recombinant protein vaccine of zhifeilong Kema or the adenovirus vector vaccine of Cansino Biologics Inc(688185) for sequential immunization.
The so-called sequential booster immunization, also known as source booster immunization, refers to the use of vaccines with different technical routes from basic immunization. The vaccination program can improve the immune effect, enhance the body’s immunity to the mutant strain, and enable the vaccinator to obtain a sustained immune response.
Based on the existing covid-19 vaccine, how to improve the resistance to Omicron variant? Sequential immunization has become one of the important exploration directions. Previously, the news released by the World Health Organization showed that many countries and regions around the world have approved the enhanced vaccination strategy of heterologous sequential immunization.
At the press conference of the joint prevention and control mechanism of the State Council, Wang Huaqing, chief expert of immunization planning of the China Center for Disease Control and prevention, introduced that the conditions to meet the sequential strengthening of immunization are: the target is people over the age of 18; Two doses of covid-19 inactivated vaccine of Sinopharm Zhongsheng Beijing company, Beijing Kexing company and Sinopharm Zhongsheng Wuhan company have been completed; Complete 2 doses of inoculation in the whole process, and the inoculation interval shall not be less than 6 months; No booster immunization has been carried out.
On the afternoon of February 19th, Cansino Biologics Inc(688185) (688185.SH, 06185.HK) announced that its recombinant New Coronavirus vaccine (type 5 adenovirus vector), which was approved by the State Council joint defense and joint control mechanism, became China’s first COVID-19 vaccine approved for sequential immunization.
Cansino Biologics Inc(688185) said that the advantage of sequential booster immunization with adenovirus vector vaccine has been confirmed in a number of clinical studies. Previously, the results of the sequential booster immunization clinical trial carried out by the team of Jiangsu Provincial Center for Disease Control and prevention showed that the level of neutralizing antibody was 5 times higher than that of the inactivated vaccine when the inactivated vaccine was used for basic immunization and the Cansino Biologics Inc(688185) biological adenovirus vector covid-19 vaccine was used for sequential booster immunization. After two doses of inactivated vaccine, one dose of keweisha was injected as reinforcement. After 14 days, the neutralizing antibody level was 197.4 (95% CI 167.7232.4). If the third dose was strengthened with inactivated vaccine, the antibody level was 33.6 (95% CI 28.3, 39.8).
At present, in addition to zhifeilong KOMA’s recombinant protein vaccine and Cansino Biologics Inc(688185) adenovirus vector vaccine, which can be used for sequential immunization, other pharmaceutical enterprises are also developing covid-19 vaccine booster needle, which has also become the next covid-19 vaccine market for pharmaceutical enterprises.
For example, on the afternoon of February 18, Zhu Baoguo, chairman of Joincare Pharmaceutical Group Industry Co.Ltd(600380) Pharmaceutical Group, told the first financial reporter that as of February 18, the company had begun to submit the listing application of v-01 as the sequential booster of covid-19 vaccine to the Chinese evaluation department, and the listing application to other countries was also in progress.
In addition, on February 14, clover biology also announced that the company plans to complete the development of covid-19 candidate vaccine as a universal booster needle in 2022, so that it can be used as a booster needle no matter what kind of technical vaccine for basic immunization or whether it has a previous covid-19 infection history.
